درباره ما   تماس با ما     پيوندها     تازه ها و اخبار  
 

In The Name of God

Address: Internal Medicine department, Endocrinology and metabolism ward, Imam Khoemeni Medical center , Vali-Asr Hospital, Tehran, Iran       

Tel:  0098-21- 22395398        Fax: 0098-21-88428951            E-mail: esteghamati@tums.ac.ir   


GENERAL INFORMATION: 

Name:  Alireza Esteghamati

Qualification:  Fellow of Endocrinology – Internal Medicine    

Marital status: Married                     Children: 1

Nationality: Iranian

Date of birth:  1961                        

Degree: Professor of Internal Medicine, Endocrinology and Metabolism

Place of birth:  Rasht, Gilan Province

EDUCATION:

* M.D.

  1986

  Tehran University of Medical Sciences (TUMS)

*Internal Medicine (Specialty)/ Fellowship of Endocrinology

  1991

  Tehran University of Medical Sciences

  

 HONORS AND DISTINCTIONS:

*Introduced as “Selected as best paper “, Evicena award, TUMS

*Introduced as “Selected best educational process third Mottahari Educational award year 1389 TUMS 

*Award for the best researcher, Iran Endocrine society year 1390 (2011)

*Award for second best paper from Iranian academy of medical sciences 1390 (2012)

*Award for best researcher from 19th Razi research festival on medical sciences (2014)

* Award for best researcher from national diabetes network 2016

* Award for nationally recognized prominent and best researches Aburyhan Festival 2016

*Award of best researcher in the field of diabetes from Iranian Diabetes Network 2016

 

MAJOR ADMINISTRATIVE RESPONSIBILITIES/ MEMBERSHIPS:

Past Director General of Education Development Center Ministry of Health and Medical  

Education (MOH), during1997-2000 

Past Director of National Medical Societies MOH 1997- 2000 

Past associate Dean of Medical School (TUMS) 2005-2008 

Member of National Diabetes Committee since 1999 till now 

Consultant of Center for Disease Management, MOH since 1999 till now 

Member of Board of Directors of Iran Endocrine Society since 2002 till now 

Member of Board of Directors of Iranian Society of Internal Medicine since 2001 till now 

Member of National Council for Drug evaluation and approval since 2004 till now 

Director of sport medicine group and head of national board of sport medicine since 2006 till now 

Member of national board examination since 2000 till now 

Research deputy, internal medicine department 2010 till now 

Member of curriculum development in deputy for education MOH  2008 till now 

And member of many committees in the ministry of health and Tehran University of Medical Sciences and secretary of many national medical congress

SCIENTIFIC EXPERIENCES:

*Thesis Supervision: more than 80 theses

*Participation in national research projects.

 

TEACHING EXERIECES:

*Professor – Department of Internal Medicine, Endocrine ward, Medical school, Tehran University of Medical Sciences and Health Services.

 

 

WOR EXPERIENCES:

*More than 25 years of experience in professional fields (as a physician)

 

  

PUBLICATIONS:

 Publications in international journals

1-Effect of renal transplantation on sperm quality and sex hormone levels.

Akbari F, Alavi M, Esteghamati A, Mehrsai A, Djaladat H, Zohrevand R, Pourmand G.

BJU Int. 2003 Aug;92(3):281-3  

2-Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome.

Esteghamati A, Abbasi M, Nakhjavani M, Yousefizadeh A, Basa AP, Afshar H.

Cardiovasc Diabetol. 2006 Jul 17;5:15

3-The association between urodynamic findings and microvascular complications in patients with long-term type 2 diabetes but without voiding symptoms.

Esteghamati A, Rashidi A, Nikfallah A, Yousefizadeh A.

Diabetes Res Clin Pract. 2007 Oct;78(1):42-50. Epub 2007 Mar 19.

4-The relationship between the insertion/deletion polymorphism of the ACE gene and hypertension in Iranian patients with type 2 diabetes.

Nakhjavani M, Esfahanian F, Jahanshahi A, Esteghamati A, Nikzamir AR, Rashidi A, Zahraei M.

Nephrol Dial Transplant. 2007 Sep;22(9):2549-53. Epub 2007 May 3.

5-Constant magnetic field of 50 mT does not affect weight gain and blood glucose level in BALB/c mice.

Abbasi M, Nakhjavani M, Hamidi S, Tarafdari AM, Esteghamati A.

Med Sci Monit. 2007 Jul;13(7):BR151-4.

6-Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran.

Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, Safaie A, Forouzanfar M, Gregg EW.

Diabetes Care. 2008 Jan;31(1):96-8. Epub 2007 Oct 5.

7-Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition.

Nikzamir A, Nakhjavani M, Esteghamati A, Rashidi A.

Nephrol Dial Transplant. 2008 Apr;23(4):1274-7. Epub 2007 Nov 6

8-Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran.

Esteghamati A, Abbasi M, Alikhani S, Gouya MM, Delavari A, Shishehbor MH, Forouzanfar M, Hodjatzadeh A, Ramezani RD.

Am J Hypertens. 2008 Jun;21(6):620-6. Epub 2008 May 1

9-HbA1c negatively correlates with LCAT activity in type 2 diabetes.

Nakhjavani M, Esteghamati A, Esfahanian F, Ghanei A, Rashidi A, Hashemi S.

Diabetes Res Clin Pract. 2008 Jul;81(1):38-41. Epub 2008 May 15.

10-The relationship between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative retinopathy in type 2 diabetes.

Feghhi M, Nikzamir A, Esteghamati A, Farahi F, Nakhjavani M, Rashidi A.

Diabetes Res Clin Pract. 2008 Sep;81(3):e1-4. Epub 2008 Jun 9.

11-HOMA-estimated insulin resistance is associated with hypertension in Iranian diabetic and non-diabetic subjects.

Esteghamati A, Khalilzadeh O, Abbasi M, Nakhjavani M, Novin L, Esteghamati AR.

Clin Exp Hypertens. 2008 Jul;30(5):297-307.

12-Albuminuria and its correlates in an Iranian type 2 diabetic population.

Nakhjavani M, Esteghamati A, Esfahanian F, Aghamohammadzadeh N, Hamidi S, Meysamie A, Abbasi M.

Lipids Health Dis. 2008 Aug 10;7:28

13-Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults.

Esteghamati A, Ashraf H, Rashidi A, Meysamie A.

Diabetes Res Clin Pract. 2008 Oct;82(1):104-7. Epub 2008 Aug 15

 

14-Metabolic syndrome and insulin resistance significantly correlate with body mass index.

Esteghamati A, Khalilzadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A.

Arch Med Res. 2008 Nov;39(8):803-8

15-Pretibial myxedema is associated with polymorphism in exon 1 of CTLA-4 gene in patients with Graves' ophthalmopathy.

Khalilzadeh O, Mojazi Amiri H, Tahvildari M, Anvari M, Esteghamati A, Mobarra Z, Tehranchinia Z, Rashidi A, Amirzargar A.

Arch Dermatol Res. 2009 Nov;301(10):719-23. Epub 2008 Nov 27.

16-Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: a cross-sectional study.

Nakhjavani M, Esteghamati A, Asgarani F, Khalilzadeh O, Nikzamir A, Safari R.

Transl Res. 2009 Feb;153(2):86-90. Epub 2008 Dec 9

17-Insulin resistance is an independent correlate of increased urine albumin excretion: a cross-sectional study in Iranian Type 2 diabetic patients.

Esteghamati A, Ashraf H, Nakhjavani M, Najafian B, Hamidi S, Abbasi M.

Diabet Med. 2009 Feb;26(2):177-81

18-Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance.

Esteghamati A, Ashraf H, Esteghamati AR, Meysamie A, Khalilzadeh O, Nakhjavani M, Abbasi M.

Diabetes Res Clin Pract. 2009 Jun;84(3):279-87. Epub 2009 Apr 9

19-Association of serum leptin levels with homeostasis model assessment-estimated insulin resistance and metabolic syndrome: the key role of central obesity.

Esteghamati A, Khalilzadeh O, Anvari M, Rashidi A, Mokhtari M, Nakhjavani M.

Metab Syndr Relat Disord. 2009 Oct;7(5):447-52.

 

20-The economic costs of diabetes: a population-based study in Tehran, Iran.

Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, Alaeddini F.

Diabetologia. 2009 Aug;52(8):1520-7. Epub 2009 May 28.

21-Metabolic syndrome is independently associated with microalbuminuria in type 2 diabetes.

Esteghamati A, Rashidi A, Khalilzedeh O, Ashraf H, Abbasi M.

Acta Diabetol. 2009 May 29. [Epub ahead of print]

22-Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia.

Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, Kamgar M, Gouya MM, Abbasi M.

BMC Public Health. 2009 May 29;9:167

23-Association between physical activity and metabolic syndrome in Iranian adults: national surveillance of risk factors of noncommunicable diseases (SuRFNCD-2007).

Esteghamati A, Khalilzadeh O, Rashidi A, Meysamie A, Haghazali M, Abbasi M, Asgari F, Gouya MM.

Metabolism. 2009 Sep;58(9):1347-55. Epub 2009 Jun 18.

24-The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes.

Nikzamir A, Esteghamati A, Feghhi M, Nakhjavani M, Rashidi A, Reza JZ.

J Renin Angiotensin Aldosterone Syst. 2009 Jun;10(2):109-14.

 

25-Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients.

Esteghamati A, Khalilzadeh O, Mobarra Z, Anvari M, Tahvildari M, Amiri HM, Rashidi A, Solgi G, Parivar K, Nikbin B, Amirzargar A.

Eur J Intern Med. 2009 Jul;20(4):424-8. Epub 2009 Feb 20

26-Optimal waist circumference cut-offs for the diagnosis of metabolic syndrome in Iranian adults: results of the third national survey of risk factors of non-communicable diseases (SuRFNCD-2007).

Esteghamati A, Abbasi M, Rashidi A, Meysamie A, Khalilzadeh O, Haghazali M, Asgari F, Nakhjavani M.

Diabet Med. 2009 Jul;26(7):745-6. No abstract available.

27-Changes in growth hormone and insulin-like growth factor-I levels in the acute stage after open heart surgery and at the time of discharge.

Nakhjavani M, Esteghamati A, Hamidi S, Esfahanian F, Nabavi H, Abbasi M, Mirkhani SH.

Exp Clin Endocrinol Diabetes. 2009 Sep;117(8):413-6. Epub 2009 Jul 16

28-Graves' ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist.

Khalilzadeh O, Anvari M, Esteghamati A, Mahmoudi M, Tahvildari M, Rashidi A, Khosravi F, Amirzargar A.

Clin Experiment Ophthalmol. 2009 Aug;37(6):614-9.

 

 

29-Association between physical activity and insulin resistance in Iranian adults: National Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007).

Esteghamati A, Khalilzadeh O, Rashidi A, Meysamie A, Haghazali M, Asgari F, Abbasi M, Rastad S, Gouya MM.

Prev Med. 2009 Sep 8. [Epub ahead of print]

30-Association of macroalbuminuria with oxidized LDL and TGF-beta in type 2 diabetic patients: a case-control study.

Nakhjavani M, Esteghamati A, Khalilzadeh O, Asgarani F, Mansournia N, Abbasi M.

Int Urol Nephrol. 2009 Sep 19. [Epub ahead of print]

31-Genetic susceptibility to Graves' ophthalmopathy: the role of polymorphisms in proinflammatory cytokine genes.

Anvari M, Khalilzadeh O, Esteghamati A, Esfahani SA, Rashidi A, Etemadi A, Mahmoudi M, Amirzargar AA.

Eye (Lond). 2009 Oct 2. [Epub ahead of print]

32-Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.

Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P.

Br J Clin Pharmacol. 2009 Oct;68(4):634-7

33-Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves' disease.

Khalilzadeh O, Anvari M, Momen-Heravi F, Esteghamati A, Rashidi A, Mahmoudi M, Nikbin B, Amirzargar A.

Clin Exp Med. 2009 Oct 31. [Epub ahead of print]

 

 

34-Menopause is an independent predictor of metabolic syndrome in Iranian women.

Eshtiaghi R, Esteghamati A, Nakhjavani M.

Maturitas. 2009 Dec 2.

 

35- Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: results in 142 patients.

Rashidi A, Nakhjavani M, Esteghamati A, Asgarani F, Khalilzadeh O, Abbasi M, Safari R.

J Nephrol. 2009 Nov-Dec;22(6):733-8.

 

36- Pattern of tobacco use among Iranian adult population: results of the national Survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007).

Meysamie A, Ghaletaki R, Haghazali M, Asgari F, Rashidi A, Khalilzadeh O, Esteghamati A, Abbasi M.

Tob Control. .

PMID: 20008159 [PubMed - as supplied by publisher]

 

 

37- Secular Trends of Obesity in Iran Between 1999 and 2007: National Surveys of Risk Factors of Non-Communicable Diseases.

Esteghamati A, Khalilzadeh O, Mohammad K, Meysamie A, Rashidi A, Kamgar M, Abbasi M, Asgari F, Haghazali M.

Metab Syndr Relat Disord. 2010 Jan 19. [Epub ahead of print]PMID: 20085488 [PubMed - as supplied by publisher]

 

 

 

38- Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007).

Esteghamati A, Khalilzadeh O, Ashraf H, Zandieh A, Morteza A, Rashidi A, Meysamie A, Nakhjavani M.

Metabolism. 2010 May 22. [Epub ahead of print]PMID: 20580780 [PubMed - as supplied by

 

39-The relationship between ACE gene insertion/deletion polymorphism and diabetic retinopathy in Iranian patients with type 2 diabetes.

Nikzamir A, Rashidi A, Esteghamati A, Nakhjavani M, Golmohammadi T, Khalilzadeh O.

Ophthalmic Genet. 2010 Jun 21. [Epub ahead of print]PMID: 20565247 [PubMed - as supplied by

 

409- Association of plasma leptin levels and insulin resistance in diabetic women: a cross-sectional analysis in an Iranian population with different results in men and women.

Nakhjavani M, Esteghamati A, Tarafdari AM, Nikzamir A, Ashraf H, Abbasi M.

Gynecol Endocrinol. 2010 Jun 17. [Epub ahead of print]PMID: 20553219 [PubMed - as supplied by

 

41-Clustering of metabolic syndrome components in a Middle Eastern diabetic and non-diabetic population.

Esteghamati A, Zandieh A, Khalilzadeh O, Meysamie A, Ashraf H.

Diabetol Metab Syndr. 2010 Jun 8;2(1):36. [Epub ahead of print]PMID: 20529329 [PubMed - as supplied by publisher]Free ArticleRelated citations

 

 

42-Increased serum HSP70 levels are associated with the duration of diabetes.

Nakhjavani M, Morteza A, Khajeali L, Esteghamati A, Khalilzadeh O, Asgarani F, Outeiro TF.

Cell Stress Chaperones. 2010 May 23. [Epub ahead of print]PMID: 20496051 [PubMed - as supplied by

 

43- ADMA is a correlate of insulin resistance in early-stage diabetes independent of hs-CRP and body adiposity.

Nakhjavani M, Karimi-Jafari H, Esteghamati A, Khalilzadeh O, Asgarani F, Ghadiri-Anari A.

Ann Endocrinol (Paris). 2010 Apr 29. [Epub ahead of print]PMID: 20434720 [PubMed - as supplied by publisher]

 

 

44-Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity.

Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Mehrabi Y, Kelishadi R, Hadaegh F.

Arch Iran Med. 2010;13(3):243-4. No abstract available. PMID: 20433230 [PubMed - in process]

 

45- The interleukin-1 family gene polymorphisms and Graves' disease.

Khalilzadeh O, Anvari M, Esteghamati A, Momen-Heravi F, Mahmoudi M, Rashidi A, Amiri HM, Ranjbar M, Tabataba-Vakili S, Amirzargar A.

Ann Endocrinol (Paris). 2010 Apr 16. [Epub ahead of print]PMID: 20400062 [PubMed - as supplied by

 

 

46- Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007).

Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, Haghazali M, Asgari F.

Nutr Metab (Lond). 2010 Apr 7;7:26.PMID: 20374655 [PubMed - in process]Free PMC ArticleFree textRelated citations

 

47- Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol.

Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, Dadkhahipour S.

Lipids. 2010 Apr;45(4):321-7. Epub 2010 Mar 12.PMID: 20224977 [PubMed - indexed for MEDLINE]

 

48-Type 2 diabetes mellitus duration: an independent predictor of serum malondialdehyde levels.

Nakhjavani M, Esteghamati A, Nowroozi S, Asgarani F, Rashidi A, Khalilzadeh O.

Singapore Med J. 2010 Jul;51(7):582-5.

 

49-Appropriate Definition of Metabolic Syndrome among Iranian Adults: Report of the Iranian National Committee of Obesity.

Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Zabetian A, Mehrabi Y, Kelishadi R, Aghajani H.

Arch Iran Med. 2010 Sep; 13(5): 426-8.

 

50-The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study - the Iran subgroup of the IMPROVE study.

Esteghamati A, Rajabian R, Amini M, Bahrami A, Khamseh ME, Afkhami-Ardekani M, Rizi EP. Endokrynol Pol.   2010 Jul-Aug;  61(4):364-70  

 

51-Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter?

Nakhjavani M, Morteza A, Meysamie A, Esteghamati A, Khalilzadeh O, Esfahanian F, Khajeali L, Feiz F.

Cell Stress Chaperones. 2010 Sep 26. [Epub ahead of print]

 

52-Insulin resistance and breast carcinogenesis: a cross-sectional study among Iranian women with breast mass.

Abbasi M, Tarafdari A, Esteghamati A, Vejdani K, Nakhjavani M.

Metab Syndr Relat Disord. 2010 Oct;8(5):411-6.

 

53-Oxidized Low-Density Lipoprotein Is Negatively Correlated With Lecithin-Cholesterol Acyltransferase Activity in Type 2 Diabetes Mellitus.

Nakhjavani M, Asgharani F, Khalilzadeh O, Esteghamati A, Ghaneei A, Morteza A, Anvari M.

Am J Med Sci. 2010 Sep 30.

 

54-Trends of diabetes according to body mass index levels in Iran: results of the national Surveys of Risk Factors of Non-Communicable Diseases (1999-2007).

Esteghamati A, Ashraf H, Khalilzadeh O, Rshidi A, Mohammad K, Asgari F, Abbasi M.

Diabet Med. 2010 Nov;27(11):1233-40. doi: 10.1111/j.1464-5491.2010.03103.x

 

55-Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ.

Anvari M, Khalilzadeh O, Esteghamati A, Momen-Heravi F, Mahmoudi M, Esfahani SA, Rashidi A, Amirzargar A.

Endocrine. 2010 Apr;37(2):344-8. Epub 2010 Mar 5

 

56-Clustering of leptin and physical activity with components of metabolic syndrome in Iranian population: an exploratory factor analysis.

Esteghamati A, Zandieh A, Khalilzadeh O, Morteza A, Meysamie A, Nakhjavani M, Gouya MM.

Endocrine. 2010 Oct;38(2):206-13. Epub 2010 Jul 11

 

 

57-Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.

Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, Morteza A, Nakhjavani M.

Diabetol Metab Syndr. 2010 Nov 3;2:65

 

58-Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study.

Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M.

Hepatol Int. 2010 Jul 25;4(3):634-40

 

 

59-Genetic susceptibility to Graves' ophthalmopathy: The role of polymorphisms in anti-inflammatory cytokine genes.

Khalilzadeh O, Anvari M, Esteghamati A, Momen-Heravi F, Rashidi A, Amiri HM, Tahvildari M, Mahmoudi M, Amirzargar A.

Ophthalmic Genet. 2010 Dec;31(4):215-20

 

 

 

60-Insulin Resistance Is Independently Associated with Liver Aminotransferases in Diabetic Patients Without Ultrasound Signs of Nonalcoholic Fatty Liver Disease.

Esteghamati A, Noshad S, Khalilzadeh O, Khalili M, Zandieh A, Nakhjavani M.

Metab Syndr Relat Disord. 2010 Nov 20. [Epub ahead of print]

 

61-Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.

Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, Meysamie A.

Diabetes Res Clin Pract. 2010 Nov 29. [Epub ahead of print]

 

62-Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type-2 Diabetes.

Nakhjavani M, Morteza A, Esteghamati A, Khalilzadeh O, Zandieh A, Safari R.

Lipids. 2010 Dec 14. [Epub ahead of p

 

63- Physical activity in Iran: results of the third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007).

Esteghamati A, Khalilzadeh O, Rashidi A, Kamgar M, Meysamie A, Abbasi M.

J Phys Act Health. 2011 Jan;8(1):27-35

64- Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007).Esteghamati A, Zandieh A, Zandieh B, Khalilzadeh O, Meysamie A, Nakhjavani M, Gouya MM.

Endocrine. 2011 Aug;40(1):117-23. Epub 2011 Mar 8.

 

65- Epidemiology and risk factors of the cardiometabolic syndrome in the Middle East.

Ashraf H, Rashidi A, Noshad S, Khalilzadeh O, Esteghamati A. Expert Rev Cardiovasc Ther. 2011 Mar;9(3):309-20. Review

66- The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus. Nikzamir A, Esteghamati A, Hammedian AA, Mahmoudi T.Mol Biol Rep. 2011 May 12.

 

67- Association of serum cortisol levels with parameters of metabolic syndrome in men and women.Esteghamati A, Morteza A, Khalilzadeh O, Noshad S, Novin L, Nakhjavani M.

Clin Invest Med. 2011 Jun 1;34(3):E131-7

 

68- Serum interleukin-1 and interleukin-6 are correlated neither with oxidized low density lipoprotein, nor with low-grade inflammation in patients with type 2 diabetes.

Morteza A, Nakhjavani M, Ghadiri-Anari A, Esteghamati A, Khalilzadeh O.

Eur Cytokine Netw. 2011 Jun 1;22(2):107-12.

 

69- Contribution of Serum Leptin to Metabolic Syndrome in Obese and Nonobese Subjects.

Esteghamati A, Noshad S, Khalilzadeh O, Morteza A, Nazeri A, Meysamie A, Esteghamati A, Nakhjavani M. Arch Med Res. 2011 Apr;42(3):244-51

70- Association of +45(T/G) and +276(G/T) polymorphisms in the adiponectin gene with coronary artery disease in a population of Iranian patients with type 2 diabetes. Esteghamati A, Mansournia N, Nakhjavani M, Mansournia MA, Nikzamir A, Abbasi M. Mol Biol Rep. 2011 Jul 10.

 

71- Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Feghhi M, Nikzamir A, Esteghamati A, Mahmoudi T, Yekaninejad MS. Transl Res. 2011 Aug;158(2):85-91. Epub 2011 Apr 1.

 

72- Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients. Nakhjavani M, Morteza A, Asgarani F, Mokhtari A, Esteghamati A, Khalilzadeh O, Rahbari G. Redox Rep. 2011;16(5):193-200

 

73- Comparing Abilities of Different Lipid Measures in Diagnosis of Insulin Resistance: A Survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) Study. Esteghamati A, Zandieh A, Zandieh B, Khalilzadeh O, Esteghamati S, Meysamie A, Nakhjavani M. Metab Syndr Relat Disord. 2012 Feb;10(1):63-9. Epub 2011 Oct 19

 

74-Patterns of fruit and vegetable consumption among Iranian adults: a SuRFNCD-2007 study. Esteghamati A, Noshad S, Nazeri A, Khalilzadeh O, Khalili M, Nakhjavani M.

Br J Nutr. 2011 Oct 10:1-5.

 

75- Gender Difference in Albuminuria and Ischemic Heart Disease in Type 2 Diabetes.

Nakhjavani M, Morteza A, Jenab Y, Ghaneei A, Esteghamati A, Karimi M, Farokhian A.

Clin Med Res. 2011 Oct 26.

 

76- Vascular endothelial growth factor (VEGF) +405 C/G polymorphism is associated with essential hypertension in a population from Tehran of Iran. Hamedian AA, Esteghamati A, Noshad S, Mozafari M, Moin-Tavakkoli H, Nakhjavani M, Mahmoudi T, Nikzamir M, Safary R, Nikzamir A. Mol Biol Rep. 2011 Dec 31.

77-The dual behavior of heat shock protein 70 and asymmetric dimethylarginine in relation to serum CRP levels in type 2 diabetes. Nakhjavani M, Morteza A, Asgarani F, Khalilzadeh O, Ghazizadeh Z, Bathaie SZ, Esteghamati A. Gene. 2012 Apr 25;498(1):107-11. Epub 2012 Feb 13

78-Apolipoproteins a-I and B as components of metabolic syndrome with respect to diabetes status: a factor analysis. Esteghamati A, Zandieh A, Esteghamati A, Sadaghiani MS, Zandieh B, Rezaeitabar E, Nakhjavani M. Metab Syndr Relat Disord. 2012 Aug;10(4):280-

79- Physical inactivity is correlated with levels of quantitative C-reactive protein in serum, independent of obesity: results of the national surveillance of risk factors of non-communicable diseases in Iran. Esteghamati A, Morteza A, Khalilzadeh O, Anvari M, Noshad S, Zandieh A, Nakhjavani M. J Health Popul Nutr. 2012 Mar;30(1):66-72.

80- The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, Nakhjavani M, Jamali A, Esteghamati AR, Khalilzadeh O. J Cardiovasc Transl Res. 2012 Aug;5(4):541-6. Epub 2012 May 15

81-Amygdalin inhibits angiogenesis in the cultured endothelial cells of diabetic rats. Mirmiranpour H, Khaghani S, Zandieh A, Khalilzadeh OO, Gerayesh-Nejad S, Morteza A, Esteghamati A. Indian J Pathol Microbiol. 2012 Apr-Jun;55(2):211-4. doi: 10.4103/0377-4929.97874.

82-Appropriate BMI cut-off values for identification of metabolic risk factors: Third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Zandieh A, Esteghamati A, Morteza A, Noshad S, Khalilzadeh O, Gouya MM, Nakhjavani M. Ann Hum Biol. 2012 Sep 5.

83- Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Esteghamati A, Eskandari D, Mirmiranpour H, Noshad S, Mousavizadeh M, Hedayati M, Nakhjavani M. Clin Nutr. 2012 Aug 21.

84-Accuracy of Anthropometric Parameters in Identification of High-Risk Patients Predicted With Cardiovascular Risk Models. Esteghamati A, Mousavizadeh M, Noshad S, Shoar S, Khalilzadeh O, Nakhjavani M. Am J Med Sci. 2012 Sep 14

85--Diabetes induces gender gap on LCAT levels and activity. Nakhjavani M, Morteza A, Karimi R, Banihashmi Z, Esteghamati A. Life Sci. 2012 Nov 7. doi:pii: S0024-3205(12)00653-4. 10.1016/j.lfs.2012.10.026

86-Gender-dependent Effects of Metformin on Vaspin and Adiponectin in Type 2 Diabetes Patients: A Randomized Clinical Trial. Esteghamati A, Mousavizadeh M, Noshad S, Zandieh A, Zarei H, Nakhjavani M. Horm Metab Res. 2012 Dec 7.

87-Treatment with pioglitazone is associated with decreased preprandial ghrelin levels: A randomized clinical trial. Taslimi S, Esteghamati A, Rashidi A, Tavakkoli HM, Nakhjavani M, Kebriaee-Zadeh A. Peptides. 2012 Dec 28;40C:89-92. doi: 0.1016/j.peptides.2012.12.020.

88-Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M. Regul Pept. 2013 Jan 14;182C:1-6. doi: 10.1016/j.regpep.2012.12.005.

89- Inconsistency in albuminuria predictors in type 2 diabetes: a comparison between neural network and conditional logistic regression. Morteza A, Nakhjavani M, Asgarani F, Carvalho FL, Karimi R, Esteghamati A. Transl Res. 2013 Jan 15. doi:pii: S1931-5244(12)00449-5. 10.1016/j.trsl.2012.12.013

90-The Inverse Relation of CA-125 to Diabetes, Metabolic Syndrome, and Associated Clinical Variables. Esteghamati A, Seyedahmadinejad S, Zandieh A, Esteghamati A, Gharedaghi MH, Sadaghiani MS, Saadipoor A, Nakhjavani M. Metab Syndr Relat Disord. 2013 Aug;11(4):256-61. doi: 10.1089/met.2012.0058. Epub 2013 Apr 6.

91- A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis. Khoshnood A, Nasiri Toosi M, Faravash MJ, Esteghamati A, Froutan H, Ghofrani H, Kalani M, Miroliaee A, Abdollahi A, Yasir A. Hepat Mon. 2013 Feb 23;13(2):e6181. doi: 10.5812/hepatmon.6181. Print 2013 Feb

 

92- Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population.

Malekzadeh MM, Etemadi A, Kamangar F, Khademi H, Golozar A, Islami F, Pourshams A, Poustchi H, Navabakhsh B, Naemi M, Pharoah PD, Abnet CC, Brennan P, Boffetta P, Dawsey SM, Esteghamati A, Malekzadeh R. J Hypertens. 2013 May 13. [Epub ahead of print]

 

93-The lost correlation between leptin and CRP in type 2 diabetes.

Morteza A, Nakhjavani M, Asgarani F, Ghaneei A, Esteghamati A, Mirmiranpour H. Eur Cytokine Netw. 2013 Mar;24(1):53-9. doi: 10.1684/ecn.2013.0329.

 

94-Heat shock protein 70 and albuminuria in patients with type 2 diabetes: a matched case control study.

Morteza A, Nakhjavani M, Larry M, Nargesi AA, Esteghamati A.

Cell Stress Chaperones. 2013 May 17. [Epub ahead of print]

 

95-The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients.

 Kolahdouz Mohammadi R, Hosseinzadeh-Attar MJ, Eshraghian MR, Nakhjavani M, Khorami E, Esteghamati A. Minerva Gastroenterol Dietol. 2013 Jun;59(2):231-6.

 

96-Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes.

 Noshad S, Mousavizadeh M, Mozafari M, Nakhjavani M, Esteghamati A. J Hum Hypertens. 2013 Jul 18. doi: 10.1038/jhh.2013.36. [Epub ahead of print]

 

97-Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects.

Esteghamati A, Arefzadeh A, Zandieh A, Salehi Sadaghiani M, Noshad S, Nakhjavani M. J Endocrinol Invest. 2013 Jul-Aug;36(7):474-7

 

98- Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial.

Mirmiranpour H, Mousavizadeh M, Noshad S, Ghavami M, Ebadi M, Ghasemiesfe M, Nakhjavani M, Esteghamati A. J Diabetes Complications. 2013 Sep-Oct;27(5):501-7. doi: 10.1016/j.jdiacomp.2013.05.006. Epub 2013 Jul 23.

 

99-Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.

Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.

Nephrol Dial Transplant. 2013 Nov;28(11):2823-33. doi: 10.1093/ndt/gft281. Epub 2013 Sep 5.

 

100- Gender-specific changes in physical activity pattern in Iran: national surveillance of risk factors of non-communicable diseases (2007-2011).

Koohpayehzadeh J, Etemad K, Abbasi M, Meysamie A, Sheikhbahaei S, Asgari F, Noshad S, Hafezi-Nejad N, Rafei A, Mousavizadeh M, Khajeh E, Ebadi M, Nakhjavani M, Esteghamati A.

Int J Public Health. 2013 Dec 18

 

101- Clinical lipid control success rate before and after percutaneous coronary intervention in iran; a single center study.

Hosseini SK, Tahvildari M, Alemzadeh Ansari MJ, Nakhjavani M, Esteghamati A, Lotfi Tokaldany M.

Iran Red Crescent Med J. 2013 Jun;15(6):467-72. doi: 10.5812/ircmj.3370. Epub 2013 Jun 5.

 

102- Serum Uric Acid, the Metabolic Syndrome, and the Risk of Chronic Kidney Disease in Patients with Type 2 Diabetes.

Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N, Nakhjavani M, Esteghamati A.

Metab Syndr Relat Disord. 2014 Jan 21. [Epub ahead of print

 

103-Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011.

Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, Asgari F, Mousavizadeh M, Rafei A, Khajeh E, Neishaboury M, Sheikhbahaei S, Nakhjavani M.

Diabetes Res Clin Pract. 2014 Jan 3. pii: S0168-8227(13)00468-3. doi: 10.1016/j.diabres.2013.12.034. [Epub ahead of print]

 

104- Comparing the Predictive Ability of Prognostic Models in Ischemic Stroke; Derivation, Validation, and Discrimination Beyond the ROC Curve.

Esteghamati A, Hafezi-Nejad N, Sheikhbahaei S, Heidari B, Zandieh A, Eslami V.

Front Neurol. 2014 Jan 27;5:9. eCollection 2014. Review.

 

105- Association of depression and anxiety with diabetes mellitus type 2 concerning some sociological factors.

Palizgir M, Bakhtiari M, Esteghamati A.

Iran Red Crescent Med J. 2013 Aug;15(8):644-8. doi: 10.5812/ircmj.12107. Epub 2013 Aug 5.

 

106-The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus.

Farshchi A, Esteghamati A, Sari AA, Kebriaeezadeh A, Abdollahi M, Dorkoosh FA, Khamseh ME, Aghili R, Keshtkar A, Ebadi M.

J Diabetes Metab Disord. 2014 Mar 4;13(1):42. doi: 10.1186/2251-6581-13-42

 

107- Homocysteine and metabolic syndrome: From clustering to additional utility in prediction of coronary heart disease.

Esteghamati A, Hafezi-Nejad N, Zandieh A, Sheikhbahaei S, Ebadi M, Nakhjavani M.

J Cardiol. 2014 Mar 13. pii: S0914-5087(14)00047-1. doi: 10.1016/j.jjcc.2014.02.001. [Epub ahead of print]

 

108-CA 19-9 is associated with poor glycemic control in diabetic patients: role of insulin resistance.

Esteghamati A, Hafezi-Nejad N, Zandieh A, Sheikhbahaei S, Emamzadeh-Fard S, Nakhjavani M.

Clin Lab. 2014;60(3):441-7

 

109- Risk of coronary heart disease associated with metabolic syndrome and its individual components in Iranian subjects: A matched cohort study.

Esteghamati A, Hafezi-Nejad N, Sheikhbahaei S, Heidari B, Zandieh A, Ebadi M, Nakhjavani M.

J Clin Lipidol. 2014 May-Jun;8(3):279-86. doi: 10.1016/j.jacl.2014.02.002. Epub 2014 Feb 15.

 

110-Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA  Dorrington RE, Driscoll TR, Ermakov SP, Esteghamati A, Faraon EJ, Farzadfar F, Felicio MM

Lancet. 2014 May 2. pii: S0140-6736(14)60696-6. doi: 10.1016/S0140-6736(14)60696-6. [Epub ahead of print]

 

111-Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: Associations with inflammatory and cardiometabolic markers in 4391 subjects.

Esteghamati A, Aryan Z, Esteghamati A, Nakhjavani M.

Diabetes Metab. 2014 May 5. pii: S1262-3636(14)00046-9. doi: 10.1016/j.diabet.2014.02.007. [Epub ahead of print]

 

112-Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes. 

Esteghamati A, Asnafi S, Eslamian M, Noshad S, Nakhjavani M.

Endocr Res. 2014 May 15:1-6.

 

113-Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes.

Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjavani M.

J Diabetes Investig. 2014 May 4;5(3):327-32. doi: 10.1111/jdi.12157.

 

114- Association of vaspin with metabolic syndrome: the pivotal role of insulin resistance.

Esteghamati A, Noshad S, Mousavizadeh M, Zandieh A, Nakhjavani M.

Diabetes Metab J. 2014 Apr;38(2):143-9. doi: 10.4093/dmj.2014.38.2.143. Epub 2014 Apr 18

 

115- Polymorphism of killer cell immunoglobulin-like receptors (KIR) and their HLA ligands in Graves' disease.

 

Dastmalchi R, Farazmand A, Noshad S, Mozafari M, Mahmoudi M, Esteghamati A, Amirzargar A.

Mol Biol Rep. 2014 Aug;41(8):5367-74. doi: 10.1007/s11033-014-3408-y. Epub 2014 May 23

 

116- Response-oriented measuring inequalities in Tehran: second round of UrbanHealth Equity Assessment and Response Tool (Urban HEART-2), concepts and framework.

Asadi-Lari M, Vaez-Mahdavi MR, Faghihzadeh S, Cherghian B, Esteghamati A, Farshad AA, Golmakani M, Haeri-Mehrizi AA, Hesari H, Kalantari N, Kamali M, Kordi R, Malek-Afzali H, Montazeri A, Moradi-Lakeh M, Motevallian A, Noorbala A, Raghfar H, Razzaghi E.

Med J Islam Repub Iran. 2013 Nov;27(4):236-48.

 

117-The degree of resistance of erythrocyte membrane cytoskeletal proteins to supra-physiologic concentrations of calcium: an in vitro study.

Mostafavi E, Nargesi AA, Ghazizadeh Z, Larry M, Farahani RH, Morteza A, Esteghamati A, Vigneron C, Nakhjavani M.

J Membr Biol. 2014 Aug;247(8):695-701. doi: 10.1007/s00232-014-9689-1. Epub 2014 Jun 15.

 

118- Response: association of vaspin with metabolic syndrome: the pivotal role of insulin resistance (diabetes metab j 2014;38:143-9).

Esteghamati A, Noshad S, Mousavizadeh M, Zandieh A, Nakhjavani M.

Diabetes Metab J. 2014 Jun;38(3):242-3. doi: 10.4093/dmj.2014.38.3.242

 

119- Revising the fasting glucose threshold for detection of cardiovascular risk factors: analysing two representative population-based studies of more than 50 000 Iranians in 3 years: The National Survey of Risk Factors for Non-Communicable Diseases of Iran.

Esteghamati A, Zandieh A, Hafezi-Nejad N, Sheikhbahaei S, Abbasi M, Gouya MM, Nakhjavani M.

Ann Hum Biol. 2014 Jul 14:1-9. [Epub ahead of print]

 

120- Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial.

Esteghamati A, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S.

J Endocrinol Invest. 2014 Aug 20.

 

121- Manual or automated sphygmomanometer? A historical cohort to quantify measurement bias in blood pressure recording.

Nargesi AA, Ghazizadeh Z, Larry M, Morteza A, Heidari F, Asgarani F, Esteghamati A, Mohammad K, Nakhjavani M.

J Clin Hypertens (Greenwich). 2014 Oct;16(10):716-21. doi: 10.1111/jch.12400. Epub 2014 Sep 8

 

 122-Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease.

Esteghamati A, Sheikhbahaei S, Hafezi-Nejad N, Mousavizadeh M, Noshad S, Gilani Larimi N, Azizi R, Nakhjavani M.

Arch Iran Med. 2014 Sep;17(9):596-601. doi: 0141709/AIM.003.

 

123- Vitamin D Deficiency is Associated with Insulin Resistance in Nondiabetics and Reduced Insulin Production in Type 2 Diabetics.

Esteghamati A, Aryan Z, Esteghamati A, Nakhjavani M.

Horm Metab Res. 2014 Sep 17. [Epub ahead of print]

 

 

124- effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.

Esteghamati A, Afarideh M, Feyzi S, Noshad S, Nakhjavani M.

Diabetes Metab Syndr. 2014 Oct 14. pii: S1871-4021(14)00086-1. doi: 10.1016/j.dsx.2014.09.009. [Epub ahead of print]

125-Metabolic syndrome in premenopausal and postmenopausal women with type 2 diabetes: loss of protective effects of premenopausal status.

Nakhjavani M, Imani M, Larry M, Aghajani-Nargesi A, Morteza A, Esteghamati A.

J Diabetes Metab Disord. 2014 Nov 23;13(1):102. doi: 10.1186/s40200-014-0102-5. eCollection 2014.

PMID: 25506584

 

126-Pulse pressure does not predict the response of diabetic nephropathy to glucose-lowering therapy.

Nakhjavani M, Nargesi AA, Heidari B, Ghazizadeh Z, Larry M, Esteghamati A.

Diab Vasc Dis Res. 2015 Mar;12(2):150-1. doi: 10.1177/1479164114559208. Epub 2014 Dec 18.

PMID: 25525076

 

 

127-Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

GBD 2013 Mortality and Causes of Death Collaborators.

Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.

PMID: 25530442

 

128-Authors' reply.

Esteghamati A, Hafezi-Nejad N, Sheikhbahaei S, Heidari B, Ebadi M, Faghihi-Kashani S, Nakhjavani M.

J Cardiol. 2015 May;65(5):440. doi: 10.1016/j.jjcc.2014.12.002. Epub 2014 Dec 29. No abstract available.

PMID:25553867

 

 

129-Appearance of leptin-HSP70 correlation, in type 2 diabetes.

Nakhjavani M, Morteza A, Nargesi AA, Mostafavi E, Esteghamati A.

Meta Gene. 2013 Oct 8;1:1-7. doi: 10.1016/j.mgene.2013.09.002. eCollection 2013 Dec.

PMID:25606369

 

130-The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.

Esteghamati A, Azizi R, Ebadi M, Noshad S, Mousavizadeh M, Afarideh M, Nakhjavani M.

Exp Clin Endocrinol Diabetes. 2015 May;123(5):289-95. doi: 10.1055/s-0034-1396864. Epub 2015 Jan 21.

PMID:25607338

 

 

131-The role of metabolic syndrome and related clinical variables in determining CEA levels.

Esteghamati A, Zandieh A, Saadipoor A, Hafezi-Nejad N, Noshad S, Esteghamati A, Seyedahmadinejad S, Nakhjavani M.

Adv Clin Exp Med. 2014 Nov-Dec;23(6):907-12. doi: 10.17219/acem/37334.

PMID:25618116

132-Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.

Hoseini SM, Kalantari A, Afarideh M, Noshad S, Behdadnia A, Nakhjavani M, Esteghamati A.

Metabolism. 2015 Apr;64(4):527-38. doi: 10.1016/j.metabol.2014.12.009. Epub 2014 Dec 30.

PMID: 2563326

 

133-Prostaglandin F2 alpha plasma concentration predicts glycemic control and oxidation status in patients with type 2 diabetes mellitus.

Nakhjavani M, Ghazizadeh Z, Nargesi AA, Mokhtari A, Asgarani F, Imani M, Davoudi Z,Esteghamati A.

Clin Lab. 2014;60(12):2073-80.

PMID:2565174

 

134-ASSOCIATION OF PERIPHERAL 5-HYDROXYINDOLE-3-ACETIC ACID, A SEROTONIN DERIVATIVE, WITH METABOLIC SYNDROME AND LOW-GRADE INFLAMMATION.

Afarideh M, Behdadnia A, Noshad S, Mirmiranpour H, Mousavizadeh M, Khajeh E, Rad MV, Mazaheri T, Nakhjavani M, Esteghamati A.

Endocr Pract. 2015 Jul;21(7):711-8. doi: 10.4158/EP14442.OR. Epub 2015 Feb 25.

PMID: 2571663

 

135-Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes.

Fathi M, Nikzamir AR, Esteghamati A, Nakhjavani M, Yekaninejad MS.

Iran Red Crescent Med J. 2015 Feb 21;17(2):e19469. doi: 10.5812/ircmj.19469. eCollection 2015 Feb.

PMID:25834741

136-An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects.

Alamdari A, Mozafari R, Tafakhori A, Faghihi-Kashani S, Hafezi-Nejad N, Sheikhbahaei S, Naderi N, Ebadi M, Esteghamati A.

Neurol Sci. 2015 Jul;36(7):1121-6. doi: 10.1007/s10072-015-2207-0. Epub 2015 Apr 8.

PMID:25851730

 

137-Complementary and alternative medicine for the treatment of obesity: a critical review.

Esteghamati A, Mazaheri T, Vahidi Rad M, Noshad S.

Int J Endocrinol Metab. 2015 Apr 20;13(2):e19678. doi: 10.5812/ijem.19678. eCollection 2015 Apr. Review.

PMID:25892995

 

138-Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Global Burden of Disease Study 2013 Collaborators.

Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7.

PMID:2606347

 

139-Hypertension and mortality in the Golestan Cohort Study: A prospective study of 50 000 adults in Iran.

Sepanlou SG, Sharafkhah M, Poustchi H, Malekzadeh MM, Etemadi A, Khademi H, Islami F, Pourshams A, Pharoah PD, Abnet CC, Brennan P, Boffetta P, Dawsey SM, Esteghamati A, Kamangar F, Malekzadeh R.

J Hum Hypertens. 2015 Jun 11. doi: 10.1038/jhh.2015.57. [Epub ahead of print]

PMID:26063561

 

 

140-Folate therapy improves the stress-to-rest mean LV volume ratio in myocardial perfusion imaging in patients with diabetes.

Emami-Ardekani A, Esteghamati A, Farzanefar S, Abousaidi M, Abbasi M, Abdollahi S, Fallahi B, Beiki D, Fard-Esfahani A, Nakhjavani M, Eftekhari M.

Ann Nucl Med. 2015 Jul 17. [Epub ahead of print]

PMID: 26184841

 

141-Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes.

Esteghamati A, Aflatoonian M, Rad MV, Mazaheri T, Mousavizadeh M, Nakhjavani M, Noshad S.

Arch Cardiovasc Dis. 2015 Jul 13. pii: S1875-2136(15)00076-5. doi: 10.1016/j.acvd.2015.01.015. [Epub ahead of print]

PMID: 26184866

 

 

 

142-Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with type 2 diabetes.

Heidari B, Nargesi AA, Hafezi-Nejad N, Sheikhbahaei S, Pajouhi A, Nakhjavani M, Esteghamati A.

Am Heart J. 2015 Sep;170(3):573-579.e5. doi: 10.1016/j.ahj.2015.06.017. Epub 2015 Jun 27.

PMID:26385042

143-Changes in Leukocyte Subpopulations with Decline in Glomerular Filtration Rate in Patients with Type 2 Diabetes.

Nakhjavani M, Aghajani Nargesi A, Salabati M, Mahmoudzadeh R, Morteza A, Heidari B,Esteghamati A.

Acta Med Iran. 2015 Jul;53(7):425-31.

PMID: 26520630

 

144-Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes.

Faghihi-Kashani S, Bonnet F, Hafezi-Nejad N, Heidari B, Aghajani Nargesi A, Sheikhbahaei S, Ebadi M, Esteghamati A.

Diabetes Metab. 2015 Oct 31. pii: S1262-3636(15)00123-8. doi: 10.1016/j.diabet.2015.10.001. [Epub ahead of print]

PMID:26531321

 

145-Non-linear contribution of serum vitamin D to symptomatic diabetic neuropathy: A case-control study.

Esteghamati A, Fotouhi A, Faghihi-Kashani S, Hafezi-Nejad N, Heidari B, Sheikhbahaei S, Zandieh A, Nakhjavani M.

Diabetes Res Clin Pract. 2015 Oct 21. pii: S0168-8227(15)00419-2. doi: 10.1016/j.diabres.2015.10.018. [Epub ahead of print]

PMID:26548603

 

146- Diabetes Care in Iran: Where We Stand and Where We Are Headed.

Noshad S, Afarideh M, Heidari B, Mechanick JI, Esteghamati A.

Ann Glob Health. 2015 Nov-Dec;81(6):839-50. doi: 10.1016/j.aogh.2015.10.003. Review.

PMID:27108151

 

147- The lost correlation between heat shock protein 70 (HSPA1A) and plasminogen activator inhibitor-1 in patients with type 2 diabetes and albuminuria.

Nargesi AA, Shalchi M, Nargesi RA, Sadeghpour N, Zarifkar M, Mozaffari M, Imani M, Esteghamati A, Nakhjavani M.

Cell Stress Chaperones. 2016 Mar;21(2):361-5. doi: 10.1007/s12192-015-0634-8. Epub 2015 Dec 4.

PMID:26637413

 

 

 

148- Contribution of vitamin D deficiency to the risk of coronary heart disease in subjects with essential hypertension.

Nargesi AA, Heidari B, Esteghamati S, Hafezi-Nejad N, Sheikhbahaei S, Pajouhi A, Nakhjavani M, Esteghamati A.

Atherosclerosis. 2016 Jan;244:165-71. doi: 10.1016/j.atherosclerosis.2015.11.020. Epub 2015 Nov 23.

PMID:26647372

 

 

 

 

149- Abdominal obesity and gestational diabetes: the interactive role of magnesium.

Mostafavi E, Nargesi AA, Asbagh FA, Ghazizadeh Z, Heidari B, Mirmiranpoor H, Esteghamati A, Vigneron C, Nakhjavani M.

Magnes Res. 2015 Dec 1;28(4):116-25. doi: 10.1684/mrh.2015.0392.

PMID:  26878251

 

150- Nonlinear relation between pulse pressure and coronary heart disease in patients with type 2 diabetes or hypertension.

Nargesi AA, Esteghamati S, Heidari B, Hafezi-Nejad N, Sheikhbahaei S, Pajouhi A, Nakhjavani M, Esteghamati A.

J Hypertens. 2016 May;34(5):974-80. doi: 10.1097/HJH.0000000000000866.

PMID: 27027382

 

151-Positive Correlation of Serum Adiponectin with Lipid Profile in Patients with Type 2 Diabetes Mellitus is Affected by Metabolic Syndrome Status.

Eslamian M, Mohammadinejad P, Aryan Z, Nakhjavani M, Esteghamati A.

Arch Iran Med. 2016 Apr;19(4):269-74. doi: 0161904/AIM.008.

PMID:27041522

 

152 -Core components of clinical education: a qualitative study with attending physicians and their residents.

Esteghamati A, Baradaran H, Monajemi A, Khankeh HR, Geranmayeh M.

J Adv Med Educ Prof. 2016 Apr;4(2):64-71.

PMID:27104200

 

153- Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients.

Esteghamati A, Momeni A, Abdollahi A, Khandan A, Afarideh M, Noshad S, Nakhjavani M.

Ann Endocrinol (Paris). 2016 Apr 19. pii: S0003-4266(16)00023-8. doi: 10.1016/j.ando.2016.01.005. [Epub ahead of print]

PMID:27106505

 

 

154-Raised serum 25-hydroxyvitamin D levels in patients with active diabetic foot ulcers.

Afarideh M, Ghanbari P, Noshad S, Ghajar A, Nakhjavani M, Esteghamati A.

Br J Nutr. 2016 Jun;115(11):1938-46. doi: 10.1017/S0007114516001094.

PMID: 27153203

 

155- The Prevalence of Metabolic Syndrome in Iran: a 2011 Update.

Noshad S, Abbasi M, Etemad K, Meysamie A, Afarideh M, Khajeh E, Asgari F, Mousavizadeh M, Rafei A, Neishaboury M, Ghajar A, Nakhjavani M, Koohpayehzadeh J, Esteghamati A.

J Diabetes. 2016 Jun 5. doi: 10.1111/1753-0407.12438. [Epub ahead of print]

PMID:27262869

 

156-Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.

Farshchi A, Aghili R, Oskuee M, Rashed M, Noshad S, Kebriaeezadeh A, Kia M, Esteghamati A.

BMC Endocr Disord. 2016 Jun 9;16(1):35. doi: 10.1186/s12902-016-0116-8.

PMID:27278922

157- Type 2 Diabetes: Model of Factors Associated with Glycemic Control.

Aghili R, Polonsky WH, Valojerdi AE, Malek M, Keshtkar AA, Esteghamati A, Heyman M, Khamseh ME.

Can J Diabetes. 2016 Jun 9. pii: S1499-2671(15)30071-X. doi: 10.1016/j.jcjd.2016.02.014. [Epub ahead of print]

PMID:27291886

 

158-Awareness, Treatment and Control of Pre-hypertension and Hypertension among Adults in Iran.

Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Khajeh E, Asgari F, Noshad S, Rafei A, Mousavizadeh M, Neishaboury MR, Afarideh M, Nakhjavani M.

Arch Iran Med. 2016 Jul;19(7):456-64. doi: 0161907/AIM.003

 

159-Diet quality in obese/overweight individuals with/without metabolic syndrome compared to normal weight controls.

Yosaee S, Esteghamati A, Nazari Nasab M, Khosravi A, Alinavaz M, Hosseini B, Djafarian K. Med J Islam Repub Iran. 2016 May 25;30:376

 

160- Family history of diabetes and the risk of coronary heart disease in people with or without type 2 diabetes.

Afarideh M, Noshad S, Ghajar A, Aryan Z, Khajeh E, Hosseini Shirvani S, Bonnet F, Esteghamati A.

Diabetes Metab. 2016 Sep 16. pii: S1262-3636(16)30471-2. doi: 10.1016/j.diabet.2016.07.032. [Epub ahead of print] No abstract available.

PMID: 27644597

 

161- The Effect of Coenzyme Q10 Supplementation on Circulating Levels of Novel Adipokine Adipolin/CTRP12 in Overweight and Obese Patients with Type 2 Diabetes.

Mehrdadi P, Kolahdouz Mohammadi R, Alipoor E, Eshraghian MR, Esteghamati A, Hosseinzadeh-Attar MJ.

Exp Clin Endocrinol Diabetes. 2016 Sep 22. [Epub ahead of print]

PMID:27657997

 

162-Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430.

Aryan Z, Noshad S, Afarideh M, Esteghamati A.

Diabetes Care. 2016 Oct;39(10):e189. doi: 10.2337/dc16-1211. No abstract available.

PMID:27660132

163-Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes.

Afarideh M, Aryan Z, Ghajar A, Noshad S, Nakhjavani M, Baber U, Mechanick JI, Esteghamati A.

Atherosclerosis. 2016 Nov;254:42-51. doi: 10.1016/j.atherosclerosis.2016.09.009.

PMID:27684605

 

164- Comment on Fischer et al. Text Message Support for Weight Loss in Patients With Prediabetes: A Randomized Clinical Trial. Diabetes Care 2016;39:1364-1370.

Afarideh M, Ghajar A, Noshad S, Esteghamati A.

Diabetes Care. 2016 Nov;39(11):e206. No abstract available.

PMID:27926903

 

 165- Absence of a positive correlation between CRP and leptin in rheumatoid arthritis.

Najafizadeh SR, Farahmand G, Roudsari AT, Heidari B, Larry M, Nargesi AA, Pajouhi A, Esteghamati A, Nakhjavani M.

Heliyon. 2016 Dec 5;2(12):e00205.

PMID:27981248

 

166- Serum 25-hydroxyvitamin D, non-alcoholic fatty liver disease and type 2 diabetes.

Afarideh M, Ghajar A, Noshad S, Saadat M, Khajeh E, Esteghamati A.

Nutr Metab Cardiovasc Dis. 2016 Sep 20. pii: S0939-4753(16)30163-6. doi: 10.1016/j.numecd.2016.09.008. [Epub ahead of print] No abstract available.

PMID: 2798635

167-Association of peripheral nesfatin-1 with early stage diabetic nephropathy.

Irannejad A, Ghajar A, Afarideh M, Khajeh E, Noshad S, Esteghamati S, Afshari K, Kahe F, Ganji M, Saadat M, Nakhjavani M, Esteghamati A.

Pathophysiology. 2016 Dec 13. pii: S0928-4680(16)30099-2. doi: 10.1016/j.pathophys.2016.12.001. [Epub ahead of print]

 

Publications in Iranian journals

 

1-Correlation between oxidized-LDL and interleukin-6 in type 2 diabetic patients 

Ghadiri-Anari A ،  Behjati J ،  Esteghamati A ،  Esfahanian F ،  Khazaiipoor Z ،  Nakhjavani M

Journal of Diabetes and Metabolic Disorders

2-The relationship of Extracellular- Superoxide Dismutase enzyme (EC-SOD) with oxidized- low density lipoprotein in type 2 diabetes with macro and normoalbuminuria

Asgarani F ،  Khajeali L ،  Esfahanian F ،  Vosogh MH ،  Esteghamati AR ،  Nakhjavani M

Tehran University Medical Journal (TUMJ)  2009;67(9) : 608-614

 

3-Plasma Level of Oxidized Low- Density Lipoprotein in Macroalbuminuric Type 2 Diabetic Patie

ts versus Normoalbuminuric Group

Nakhjavani Manoochehr ،  Asgarani Firouzeh ،  Esfahanian Fatemeh ،  Esteghamati Alireza

Acta Medica Iranica  2009;47(5) : 349-352

 

4-Exercise Prescription in Patients with Diabetes Type 2

A Esteghamati ،  M Hassabi ،  F Halabchi ،  M Bagheri

Journal of Diabetes and Metabolic Disorders (Formerly: Iranian Journal of Diabetes and Lipid Disorders)  2008;7:2

 

5-LECITHIN: CHOLESTEROL ACYLTRANSFERASE ACTIVITY IS DECREASED IN TYPE 2 DIABETES MELLITUS

A. Ghanei ،  F. Esfananian ،  A. Esteghamati ،  J. Behjati ،  S. Hamidi M. Nakhjavani

Acta Medica Iranica  2007;45(6) : 481-486

 

6-Diagnosis and Management of 253 Cases with Cushing's syndrome in Imam Khomeini Hospital

Esteghamati A.R ،  Eshtiaghi R ،  Yousefizadeh A.A ،  Nakhjavani M

Tehran University Medical Journal (TUMJ)  2007;65(7) : 77-82

 

7-EVALUATION OF FIRST PHASE NON-SURGICAL PERIODONTAL THERAPY ON DIABETES CONTROL "

Saeed Sadat Mansouri ،  Alireza Esteghamati ،  Yasaman Yousefi

Iranian Journal of Diabet

s and Lipid Disorders  2006;6(1) : 101-106

 

8-DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS: MORE ATHEROGENIC LIPID PROFILE IN WOMEN

M. Nakhjavani ،  A. R. Esteghamati ،  F. Esfahanian A. R. Heshmat

Acta Medica Iranica  2006;44(2) : 111-118

 

9-"THE EFFE

TS OF LIVER DYSFUNCTION ON SERUM LIPOPROTEIN LEVELS IN PATIENTS WITH CIRRHOSIS AND CHRONIC HEPATITIS "

Shahram Safa ،  Alireza Esteghamati ،  Mohsen Nasiri Tousi ،  Hosein Foroutan ،  Hadi Ghofrani ،  Akram Sarbyaei ،  Mehrshad Abbasi

Iranian Journal

f Diabetes and Lipid Disorders  2005;5(2) : 153-161

 

10-"THE ACTION PROFILE OF HUMAN INSULIN: AN EUGLYCEMIC CLAMP TEST APPROACH TO COMPARE TWO COMMERCIAL BIOSYNTHETIC INSULIN BRANDS "

Ali Reza Esteghamati ،  Mehrshad Abbasi ،  AbbasYousefizadeh

Irani

n Journal of Diabetes and Lipid Disorders  2005;5(1) : 59-65

 

 11-"COMPARISON OF OXIDIZED LDL AND ANTI OXIDIZED LDL ANTIBODY LEVELS BETWEEN TYPE 2 DIABETIC PATIENTS AND NORMAL PEOPLE "

Mitra Neiafar ،  Fatemeh Esfahanian ،  Alireza Esteghamati ،  Ramin Heshmat ،  Mehdi Hedayati ،  Masoumeh Karami ،  Mehrshad Abbasi ،  Manochehr Nakhjavani

Iranian Journal of Diabetes and Lipid Disorders  2005;4(4) : 21-25

 

12-Evaluation of clinical manifestations and laboratory findings of primary hyperparathyroidism

n Imam Hospital (1988-1998)

Nakhjavani M ،  Esteghamati A ،  Alam Salimi M

Tehran University Medical Journal (TUMJ)  2002;60(6) : 429-436

 

13-Evaluation of antioxidant status in Streptozotocin-induced diabetic rats by Ferric reducing ability of plasm

 assay

Zarban A ،  Doosti M ،  Esteghamati A ،  Allameh A

Acta Medica Iranica  2000;38(3) : 127-131 

14-Erythrocyte Membrane Fluidity in Ageing, Type 2 Diabetes and Stroke Patients

International Journal of Endocrinology and Metabolism. January 2008, Volume 6, Issue 1: 20-27
Original Article 

SJ Emam, AR Nikzamie, M Nakhjavani, Ar Esteghamati 

15- Correlation between parathormone and coronary artery calcium scoring and coronary artery disease

Zand Parsa AF ،  Gilani Larimi N ،  Esteghamati A ،  Motevalli M

Tehran University Medical Journal  2013;71(2) : 109-113

 

 

1 

 پروبينگ استخوان در زخمهای پای ديابتی: روش بالينی ساده‏ای برای تشخيص استئوميليت
دکتر منوچهر نخجوانی، دکتر عليرضا استقامتی، دکتر فرشاد امامی، دکتر محمد حسين‏زاده،
جلد 2, شماره 1 - ( 1-1379 

2 

 مقایسه سطح هورمونهای جنسی و اسپرموگرام قبل و بعد از پیوند موفق کلیه
دکتر غلامرضا پورمند، دکتر رويا زهره‌وند، دکتر محمد علوی، دکتر عليرضا استقامتی، دکتر عبدالرسول مهرسای، دکتر محسن طاهری محمودی،
جلد 2, شماره 4 - ( 10-1379

 

 3 

 بررسی فعالیت محورهیپوتالاموس ـ هیپوفیز ـ گناد در بیماران مبتلا به سیروز در بیمارستان امام خمینی تهران
دکتر حسين فروتن، دکتر عباس قاسمی حسينی، دکتر عليرضا استقامتی، دکتر حميدرضا محمدی، دکتر شهرام ميرمؤمن،
جلد 3, شماره 1 - ( 1-1380

 

4 

 ارزش آسپیراسیون سوزنی تیروئید در تشخیص گره‌های تیروئید
دکتر عليرضا استقامتی، دکتر عباس يوسفی‌زاده، دکتر محمد رخشان، دکتر رامين مهرداد،
جلد 3, شماره 3 - ( 7-1380 ) 

 

 ارزیابی وضعیت آنتی‌اکسیدانی وشاخص‌های استرس اکسیداتیو در بیماران مبتلا به دیابت ملیتوس نوع دو
دکتر عليرضا استقامتی، دکتر اصغر زربان، دکتر محمود دوستی،
جلد 3, شماره 4 - ( 10-1380

 

 6 

 بررسی سیر بالینی و نتایج روش‌های مختلف درمانی ندول‌های داغ
منوچهر نخجوانی، عليرضا استقامتی، رويا زمانی، هاجر سلطانی،
جلد 7, شماره 3 - ( 7-1384

 

 7 

 مقایسه روش انفوزیون 7 ساعته دگزامتازون با روش کلاسیک دو روزه
رادينا اشتياقی، عليرضا استقامتی، اميرعباس يوسفی‌زاده، منوچهر نخجوانی،
جلد 7, شماره 3 - ( 7-1384 ) 

 

 8 

 پوکی استخوان در بيماران مبتلا به بيماری مزمن کبدی: ارايه راهکار رياضی برای شناسايی بيماران پرخطر بر اساس يافته‌های بالينی
دکتر عليرضا استقامتی، دکتر رزيتا عليزاده، دکتر مهرشاد عباسی، دکتر اکبرسلطانی، دکتر حسين فروتن، دکتر باقر لاريجانی،
جلد 8, شماره 1 - ( 1-1385

 

 

9-ارتباط پلی مورفیسم ژن آدیپونکتین با بیماری عروق کرونر در بیماران مبتلا به دیابت نوع 2

مجله دیابت و لیپید ایران، زمستان 1388، دوره 9 (شماره 2): 141-137

 

علیرضا استقامتی، نسرین منصورنیا، منوچهر نخجوانی، محمدعلی منصورنیا، عبدالرحیم نیک ضمیر، عباس یوسفی زاده، رضا صفری

سال انتشار مجله: 1388

 

-10پروتئین شوك حرارتی 70 کیلودالتونی و دیابت نوع

 

، مجله  دیابت ولیپید ایران، بهار 1389،  دوره 9 (شماره 3)   2820276

 

مریم رضائی اول، علیرضا استقامتی، اعظم علمداری، افسانه مرتضی، علی پاشا میثمی،منوجهر نخجوانی

 

 

 

11بررسی رابطه سطح سرمی لیپوپروتئین با دانسیته کم اکسیده  با پروتئین  شوک حرارتی 70 کیلودالتونی (HSP70)در بیماران دیابتی نوع 2           

مجله دیابت و لیپید ایران، ویژنامه عوامل خطرساز دیابت وبیماریهای قلبی – عروقی، 1288: 21-14

اسامی نویسندگان

لیلا خواجه علی، منوچهر نخجوانی، فاطمه اصفهانیان، جواد بهجتی، علیرضا استقامتی، فیروزه عسگرانی

1389

AUTHORSHIP:

Member of writing group of  the book “WHO, Regional office for the Eastern Mediterranean. Management of Diabetes Mellitus: Standards of Care and Clinical Practice Guidelines”. 1994

 

  INTERNATIONAL CONFERENCES PRESENTATIONS/PUBLICATIONS:

 1- Prevalence of diabetes, impaired fasting glucose and obesity in Iran

M. M. Gooya1, A. Esteghamati2, A. Delavari1, S. Alikhani1, A. Moghisi1, A. Yarahmadi1, F. Alaedini1, M. Abbasi2, S. Mahdavi1, F. Azizi3;

42 th EASD annual meeting CopenhageMalmoe, Denmark-Sweden 14-17 september 2006

2- Insulin resistance and hypertension

A. R. Esteghamati, M. Abbasi, M. Nakhjavani, L. Novin, A. Yousefizadeh;

 Endocrine, Endocrinology and Metabolism Research Center, Tehran,

42 th EASD annual meeting CopenhageMalmoe, Denmark-Sweden 14-17 september 2006 

3-Relationship between oxidized low density lipoprotein and insulin resistance in type 2 diabetes mellitus

M. Nakhjavani, F. Esfahanian, A. Esteghamati, M. Niafar, M. Abbasi, H. Pordal, R. Heshmat;

Endocrinolody and Metabolism Research Center, Tehran University of Medical Sciences 

4. Esteghamati AR, Rajabian R, Amini M, Bahrami A, Khamseh ME, Afkhami Ardekani M, Parvaresh Rizi E. Biphasic insulin aspart 30 (BIAsp 30) improves glysemic control in patients with type 2 diabetes regardless of previous treatment regimen: the IMPROVE Study in Iran. American Diabetes Association 69th Scientific Sessions June 2009, New Orleans, U.S.A.

 5. Esteghamati AR, Rajabian R, Amini M, Bahrami A, Khamseh ME, Afkhami Ardekani M, Parvaresh Rizi E. Improved safety and efficacy profile in patients with type 2 diabetes treated with biphasic insulin aspart 30 (BIAsp 30): Iran subgroup of the IMPROVE Study. American Diabetes Association 69th Scientific Sessions June 2009, New Orleans, U.S.A.  

6-Cardiovascular risk factors and prediction of albuminuria in patients with type 2 diabetes, a neural network analysis

M. Nakhjavani, A. Morteza, A. Esteghamati, F. Esfahanian, F. Asgarani, O. Khalilzadeh;

Endocrine Research Center, Tehran, University of Medical Sciences, Tehran, Iran,

47th EASD annual meeting, Lisbon 2011

 REVIEWRS ACTIVITY

 Manuscript reviewer for more than 15 international and 5 national journals

 

 RESEARCH INTERESTNS:

 * Diabetes & Metabolic Syndrome

* Thyroid disorders

* Other fields of endocrinology